Page last updated: 2024-10-29

avapro and Proteinuria

avapro has been researched along with Proteinuria in 42 studies

Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.

Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.

Research Excerpts

ExcerptRelevanceReference
"This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis."9.19Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial. ( Cao, L; Chen, F; Fan, W; Feng, P; Fu, P; Gou, Z; Liang, Y; Liu, F; Qiu, H; Shi, M; Shi, P; Zhong, H; Zhou, L; Zuo, C, 2014)
"The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood."9.12Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006)
"Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago."8.83Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006)
" ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin."7.80Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014)
"Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group."5.36Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010)
"This study aims to assess the efficacy and safety of Rehmannia glutinosa acteosides used in combination with the angiotensin receptor blocker irbesartan to treat primary chronic glomerulonephritis."5.19Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial. ( Cao, L; Chen, F; Fan, W; Feng, P; Fu, P; Gou, Z; Liang, Y; Liu, F; Qiu, H; Shi, M; Shi, P; Zhong, H; Zhou, L; Zuo, C, 2014)
"The angiotensin II receptor blockers irbesartan and losartan effectively reduce blood pressure and proteinuria in childhood."5.12Candesartan cilexetil in children with hypertension or proteinuria: preliminary data. ( Bianchetti, MG; Fossali, E; Konrad, M; Rizzi, M; Simonetti, GD; von Vigier, RO, 2006)
"Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial."5.11Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005)
"In nonnephrotic NPGN patients, standard doses of either ramipril or irbesartan lead to significant reduction of residual proteinuria and amelioration of the qualitative features suggestive of tubular damage."5.10Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis. ( Balletta, MM; Bellizzi, V; Conte, G; D'Amora, M; De Nicola, L; Giannattasio, P; Iodice, C; Minutolo, R; Rinaldi, G; Signoriello, G; Tuccillo, S, 2003)
"In children with chronic kidney disease the effects of the angiotensin II antagonist irbesartan on arterial pressure and proteinuria mimic those observed with the converting enzyme inhibitors."5.09Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease. ( Bianchetti, MG; Teuffel, O; von Vigier, RO; Zberg, PM, 2000)
"Angiotensin II antagonists (AIIAs) were introduced to treat hypertension about 10 years ago."4.83Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria. ( Gavras, H; Ribeiro, AB, 2006)
" Risk factors for diabetic nephropathy are discussed, and include hyperglycemia, hypertension, angiotensin II, proteinuria, dyslipidemia, smoking, and anemia."4.82Outcome studies in diabetic nephropathy. ( Mohanram, A; Toto, RD, 2003)
"Currently, AIIAs such as losartan represent the only evidence-based treatment strategy for patients with type 2 DM and proteinuria."4.82Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. ( Ruilope, LM; Segura, J, 2003)
"SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism."4.81[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002)
" The PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; Safety and efficacy in paTieNts with hypERtension) study is a prospective specific clinical use survey examining the efficacy and safety of 12-week treatment with amlodipine (AML) and Angiotensin II Receptor Blocker (ARB) in 5900 hypertensive patients."3.81The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor ( Fukuda, H; Ishibashi, K; Ishimitsu, T; Nagao, M; Nukui, K; Sato, F; Uchida, M, 2015)
" ARB treatment ameliorates proteinuria in PAN nephropathy by inhibiting the reduction of NEPH1 and nephrin."3.80Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin. ( Fukusumi, Y; Kawachi, H; Kayaba, M; Kitazawa, Y; Takahashi, A; Tomita, M; Yamazaki, M, 2014)
"Short treatment duration, lower pretreatment proteinuria than expected."2.90Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. ( Aparicio, C; Bellasi, A; Cannata, A; Cozzolino, M; Ferrari, S; Kohan, DE; Lecchi, V; Mallamaci, F; Mazzaferro, S; Peraro, F; Perna, A; Perticucci, E; Remuzzi, G; Rotondi, S; Ruggenenti, P; Ruggiero, B; Tartaglione, L; Trillini, M; Tripepi, R; Villa, D; Zoccali, C, 2019)
" Sparsentan was safe and well tolerated."2.87DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS. ( Adler, S; Campbell, KN; Chaudhuri, A; Derebail, VK; Gambaro, G; Gesualdo, L; Gipson, DS; Hogan, J; Komers, R; Lieberman, K; Marder, B; Meyers, KE; Mustafa, E; Nelson, P; Radhakrishnan, J; Srivastava, T; Stepanians, M; Tesar, V; Trachtman, H; Zhdanova, O, 2018)
"Total effective rate in treating proteinuria in high-dose group was 72."2.76[The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease]. ( Chen, XD; Li, X; Li, ZX, 2011)
"Patients with high blood pressure are often overweight or even obese."2.71[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice]. ( Bramlage, P; Kirch, W; Sharma, AM, 2004)
"When indomethacin was added to enalapril treatment, a further significant reduction in urinary proteins and fractional albumin clearance was observed."2.69The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. ( Azzollini, N; Mister, M; Perico, N; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F, 1998)
"Patients with type 2 diabetes and diabetic nephropathy have a dramatically increased cardiovascular risk."2.42Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003)
"Recently, the Reduction of Endpoints in NIDDM (non-insulin-dependent diabetes mellitus) with the Angiotensin II Antagonist Losartan (RENAAL) trial provided sufficient data to conclude that the blockade of the All AT1 receptor with losartan confers renoprotection in patients with DM-2 and nephropathy."2.41The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. ( Ribeiro, AB; Zanella, MT, 2002)
"The Irbesartan Diabetic Nephropathy Trial (IDNT) demonstrated that irbesartan significantly slowed established Type 2 diabetic nephropathy progression."1.38Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial. ( Bain, SC; Bilous, RW; Evans, M; Hogan, S, 2012)
"Proteinuria was markedly attenuated in the sulodexide-treated groups."1.38Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. ( Chen, XM; Li, P; Ma, LL; Wang, JZ; Wei, RB; Xie, RJ; Xie, YS; Yin, M, 2012)
"Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group."1.36Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010)
"In pediatric patients with chronic kidney diseases, irbesartan given once a day for 18 weeks significantly reduces arterial pressure and proteinuria, with an excellent tolerability and side effect profile."1.31Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. ( Bianchetti, MG; Casaulta-Aebischer, C; Fossali, E; Franscini, LM; Pfister, R; Von Vigier, RO, 2002)

Research

Studies (42)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (7.14)18.2507
2000's25 (59.52)29.6817
2010's14 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hsu, FY1
Lin, FJ1
Ou, HT1
Huang, SH1
Wang, CC1
Trachtman, H1
Nelson, P1
Adler, S1
Campbell, KN1
Chaudhuri, A1
Derebail, VK1
Gambaro, G2
Gesualdo, L1
Gipson, DS1
Hogan, J1
Lieberman, K1
Marder, B1
Meyers, KE1
Mustafa, E1
Radhakrishnan, J1
Srivastava, T1
Stepanians, M1
Tesar, V1
Zhdanova, O1
Komers, R1
Ruggiero, B1
Trillini, M1
Tartaglione, L1
Rotondi, S1
Perticucci, E1
Tripepi, R1
Aparicio, C1
Lecchi, V1
Perna, A1
Peraro, F1
Villa, D1
Ferrari, S1
Cannata, A1
Mazzaferro, S1
Mallamaci, F1
Zoccali, C1
Bellasi, A1
Cozzolino, M1
Remuzzi, G3
Ruggenenti, P2
Kohan, DE1
Qiu, H1
Fu, P1
Fan, W1
Zuo, C1
Feng, P1
Shi, P1
Cao, L1
Liu, F1
Zhou, L1
Chen, F1
Zhong, H1
Gou, Z1
Liang, Y1
Shi, M1
Wang, H2
Mu, W1
Zhai, J1
Xing, D1
Miao, S1
Wang, J1
Deng, Y1
Wang, N1
Chen, H1
Yang, H1
He, X1
Shang, H1
Linz, D1
Mahfoud, F1
Linz, B1
Hohl, M1
Schirmer, SH1
Wirth, KJ1
Böhm, M1
Takahashi, A1
Fukusumi, Y1
Yamazaki, M1
Kayaba, M1
Kitazawa, Y1
Tomita, M1
Kawachi, H1
Ishimitsu, T1
Fukuda, H1
Uchida, M1
Ishibashi, K1
Sato, F1
Nukui, K1
Nagao, M1
Ferraro, PM1
Ferraccioli, GF1
Fulignati, P1
Costanzi, S1
Takai, S1
Jin, D1
Sakonjo, H1
Miyazaki, M1
Evans, M1
Bain, SC1
Hogan, S1
Bilous, RW1
Li, X1
Chen, XD1
Li, ZX1
Ros-Ruiz, S1
Aranda-Lara, P1
Fernández, JC1
Martínez-Esteban, MD1
Jironda, C1
Hidalgo, P1
Hernández-Marrero, D1
Li, P1
Ma, LL1
Xie, RJ1
Xie, YS1
Wei, RB1
Yin, M1
Wang, JZ1
Chen, XM1
Tsuruoka, S1
Kai, H1
Usui, J1
Morito, N1
Saito, C1
Yoh, K1
Yamagata, K1
Zanella, MT1
Ribeiro, AB2
Franscini, LM1
Von Vigier, RO3
Pfister, R1
Casaulta-Aebischer, C1
Fossali, E2
Bianchetti, MG3
Bernadet-Monrozies, P1
Rostaing, L1
Kamar, N1
Durand, D1
Iodice, C1
Balletta, MM1
Minutolo, R1
Giannattasio, P1
Tuccillo, S1
Bellizzi, V1
D'Amora, M1
Rinaldi, G1
Signoriello, G1
Conte, G1
De Nicola, L1
Mohanram, A1
Toto, RD1
Lewis, EJ4
Lewis, JB3
Li, S1
Cao, B1
Feng, QH1
Li, XZ1
Ruilope, LM1
Segura, J1
Hunsicker, LG3
Atkins, RC2
Braden, G2
de Crespigny, PJ1
DeFerrari, G2
Drury, P2
Locatelli, F2
Wiegmann, TB2
Lehnert, H1
Bramlage, P3
Pittrow, D1
Kirch, W2
Briganti, EM1
Champion de Crespigny, PJ1
Vogt, L1
Navis, G1
de Zeeuw, D1
de Gracia, MC1
Molina, M1
Navarro, MJ1
Garcia Hernández, MA1
Sharma, AM1
Gavras, H1
Simonetti, GD1
Konrad, M1
Rizzi, M1
Thoenes, M1
Paar, WD1
Bramlage, CP1
Schmieder, RE1
Lapinski, R1
Perico, N2
Remuzzi, A2
Sangalli, F2
Benigni, A1
Ziai, F1
Ots, M1
Provoost, AP1
Troy, JL1
Rennke, HG1
Brenner, BM1
Mackenzie, HS1
Azzollini, N1
Mister, M1
Zhou, A1
Yu, L1
Li, J1
Zhang, J1
Zberg, PM1
Teuffel, O1
Bold, KO1
De Rosa, ML1
de Cristofaro, A1
Rossi, M1
Baiano, A1
Cardace, P1
Albanese, L1
Vigorito, C1
Rodby, RA1
Ferrari, P1
Marti, HP1
Pfister, M1
Frey, FJ1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment[NCT01968759]Phase 253 participants (Actual)Interventional2013-10-31Completed
Medication Adherence Given Individual SystemCHANGE(TM) in Advancing Nephropathy (MAGICIAN) Pilot Study[NCT04616612]150 participants (Anticipated)Interventional2021-12-15Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

7 reviews available for avapro and Proteinuria

ArticleYear
The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
    Clinical therapeutics, 2002, Volume: 24, Issue:7

    Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperte

2002
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36

    Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2002
Outcome studies in diabetic nephropathy.
    Seminars in nephrology, 2003, Volume: 23, Issue:3

    Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme

2003
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Clinical and experimental nephrology, 2003, Volume: 7, Issue:1

    Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin

2003
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Clinical therapeutics, 2003, Volume: 25, Issue:12

    Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trial

2003
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
    Kidney international. Supplement, 2004, Issue:92

    Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetic Nephropathies; Humans; Irbesar

2004
Angiotensin II antagonists: clinical experience in the treatment of hypertension, prevention of cardiovascular outcomes and renal protection in diabetic nephropathy and proteinuria.
    Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds

2006

Trials

19 trials available for avapro and Proteinuria

ArticleYear
DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.
    Journal of the American Society of Nephrology : JASN, 2018, Volume: 29, Issue:11

    Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Child; Creatinine; Dose-Response R

2018
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019, Volume: 74, Issue:3

    Topics: Angiotensin-Converting Enzyme Inhibitors; Chelating Agents; Cross-Over Studies; Drug Monitoring; Dru

2019
Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial.
    Phytotherapy research : PTR, 2014, Volume: 28, Issue:1

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Blood Pressure; Female; Glomerul

2014
The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Trials, 2013, Jun-05, Volume: 14

    Topics: Administration, Oral; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Com

2013
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2009, Volume: 24, Issue:1

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biphenyl C

2009
[The efficacy and safety of high-dose irbesartan in treatment of clinical proteinuria in patients with chronic kidney disease].
    Zhonghua nei ke za zhi, 2011, Volume: 50, Issue:12

    Topics: Adult; Aged; Biphenyl Compounds; Female; Humans; Irbesartan; Male; Middle Aged; Prospective Studies;

2011
High doses of irbesartan offer long-term kidney protection in cases of established diabetic nephropathy.
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2012, Volume: 32, Issue:2

    Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Diabetic Nephropathies; Fe

2012
Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:3

    Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Biphe

2013
Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.
    Kidney international, 2003, Volume: 63, Issue:6

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Creati

2003
[IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    MMW Fortschritte der Medizin, 2003, Oct-09, Volume: 145 Suppl 3

    Topics: Adolescent; Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen

2003
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:2

    Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep

2005
Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?
    Journal of the American Society of Nephrology : JASN, 2005, Volume: 16 Suppl 1

    Topics: Adolescent; Adult; Aged; Biological Availability; Biphenyl Compounds; Confidence Intervals; Dose-Res

2005
[Effect of irbesartan in proteinuric non-diabetic renal disease].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2005, Volume: 25, Issue:5

    Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; Humans; Irbesartan; Kidn

2005
[Arterial hypertension in obese patients. Rationale for a prospective medical care study in the family doctor's practice].
    MMW Fortschritte der Medizin, 2004, Aug-05, Volume: 146 Suppl 2

    Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; C

2004
Candesartan cilexetil in children with hypertension or proteinuria: preliminary data.
    Pediatric nephrology (Berlin, Germany), 2006, Volume: 21, Issue:10

    Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Child; Chil

2006
The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Journal of the American Society of Nephrology : JASN, 1998, Volume: 9, Issue:12

    Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflam

1998
Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease.
    European journal of pediatrics, 2000, Volume: 159, Issue:8

    Topics: Adolescent; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito

2000
Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    Journal of cardiovascular pharmacology, 2001, Volume: 38, Issue:3

    Topics: Adult; Aged; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Drug Administr

2001
A clinical trial in type 2 diabetic nephropathy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001, Volume: 38, Issue:4 Suppl 1

    Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block

2001

Other Studies

16 other studies available for avapro and Proteinuria

ArticleYear
Renoprotective Effect of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Diabetic Patients with Proteinuria.
    Kidney & blood pressure research, 2017, Volume: 42, Issue:2

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds

2017
Effect of obstructive respiratory events on blood pressure and renal perfusion in a pig model for sleep apnea.
    American journal of hypertension, 2014, Volume: 27, Issue:10

    Topics: Aldosterone; Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Disea

2014
Angiotensin II type 1 receptor blockade ameliorates proteinuria in puromycin aminonucleoside nephropathy by inhibiting the reduction of NEPH1 and nephrin.
    Journal of nephrology, 2014, Volume: 27, Issue:6

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Disease Models, Animal; Diseas

2014
The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor
    Clinical and experimental hypertension (New York, N.Y. : 1993), 2015, Volume: 37, Issue:7

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure

2015
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2010, Volume: 33, Issue:9

    Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Ca

2010
Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:6

    Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Di

2012
Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure.
    Acta pharmacologica Sinica, 2012, Volume: 33, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biomarkers; Biphenyl Compounds; Blood Pressure; Bl

2012
Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases.
    American journal of hypertension, 2002, Volume: 15, Issue:12

    Topics: Adolescent; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pre

2002
[Renal protective effect of angiotensin II receptor antagonist on growth hormone-treated nephrotic rats].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2003, Volume: 41, Issue:11

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibiotics, Antineoplastic; Biphenyl Com

2003
[Albuminuria: an indicator of cardiovascular risk].
    Medizinische Klinik (Munich, Germany : 1983), 2007, Oct-15, Volume: 102, Issue:10

    Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Antihypertensi

2007
Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney.
    Journal of the American Society of Nephrology : JASN, 1996, Volume: 7, Issue:5

    Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Capillaries; Capillar

1996
The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
    Kidney international. Supplement, 1996, Volume: 57

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv

1996
Renal protective effects of blocking the intrarenal renin-angiotensin system: angiotensin II type I receptor antagonist compared with angiotensin-converting enzyme inhibitor.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2000, Volume: 23, Issue:4

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compou

2000
[Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    MMW Fortschritte der Medizin, 2001, May-31, Volume: 143, Issue:22

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as To

2001
Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
    Journal of hypertension, 2002, Volume: 20, Issue:1

    Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compound

2002
Preventing nephropathy in patients with type 2 diabetes.
    Managed care interface, 2002, Volume: 15, Issue:1

    Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Ty

2002